Alisertib + Alisertib + Alisertib + Alisertib + Alisertib + Paclitaxel
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Small Cell Lung Cancer ( SCLC )
Conditions
Small Cell Lung Cancer ( SCLC )
Trial Timeline
Sep 30, 2026 → Sep 30, 2028
NCT ID
NCT07465757About Alisertib + Alisertib + Alisertib + Alisertib + Alisertib + Paclitaxel
Alisertib + Alisertib + Alisertib + Alisertib + Alisertib + Paclitaxel is a phase 2 stage product being developed by Puma Biotechnology for Small Cell Lung Cancer ( SCLC ). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07465757. Target conditions include Small Cell Lung Cancer ( SCLC ).
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07465757 | Phase 2 | Recruiting |
Competing Products
20 competing products in Small Cell Lung Cancer ( SCLC )
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BBP-398 with nivolumab | BridgeBio Pharma | Phase 1 | 30 |
| Pemetrexed + Carboplatin | Eli Lilly | Phase 3 | 77 |
| Necitumumab + Gemcitabine + Carboplatin | Eli Lilly | Phase 2 | 52 |
| Selpercatinib | Eli Lilly | Pre-clinical | 23 |
| Pemetrexed + Cisplatin + Placebo + Pemetrexed | Eli Lilly | Phase 3 | 77 |
| NBTXR3 | Nanobiotix | Phase 1/2 | 36 |
| Pemetrexed | Eli Lilly | Pre-clinical | 23 |
| pemetrexed + erlotinib | Eli Lilly | Phase 2 | 52 |
| LY3295668 Erbumine | Eli Lilly | Phase 1 | 33 |
| FYB206 + FYB206 + Keytruda | Formycon AG | Phase 3 | 69 |
| 6-Thio-2'-Deoxyguanosine + Cemiplimab | MAIA Biotechnology | Phase 2 | 44 |
| 6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine alone | MAIA Biotechnology | Phase 3 | 69 |
| pemetrexed + cisplatin | Eli Lilly | Phase 2 | 52 |
| gemcitabine + carboplatin + cisplatin | Eli Lilly | Phase 2 | 52 |
| Cetuximab | Eli Lilly | Phase 1 | 33 |
| pemetrexed + docetaxel | Eli Lilly | Phase 3 | 77 |
| enzastaurin + pemetrexed + docetaxel + carboplatin | Eli Lilly | Phase 2 | 52 |
| PemCarbo + Pem only | Eli Lilly | Phase 3 | 77 |
| TNG456 + abemaciclib | Eli Lilly | Phase 1/2 | 41 |
| pemetrexed + cisplatin | Eli Lilly | Phase 1/2 | 41 |